Clinical Efficacy of Ertugliflozin Combined with Semaglutide in the Treatment of Type 2 Diabetes Patients with Heart Failure
Objective To investigate the clinical efficacy of ertugliflozin combined with semaglutide in the treatment of type 2 diabetes patients with heart failure.Methods 76 type 2 diabetes patients with heart failure admitted to Gao'an People's Hospital from December 2021 to October 2022 were selected,and all patients were divided into two groups according to the random number table method,with 38 cases in each group.The control group was treated with ertugliflozin orally,while the observation group was treated with semaglutide injection combined with ertugliflozin orally.Both groups were treated for 3 months.The body mass index(BMI),blood pressure,blood glucose,blood lipid,cardiac function and adverse reactions were compared between the two groups.Results There was no statistically significant difference between the two groups in terms of BMI,blood pressure,blood glucose,blood lipid and cardiac function(P>0.05).After treatment,the BMI,systolic blood pressure and diastolic blood pressure in the observation group were lower than those in the control group(P<0.05);the fasting blood glucose(FBG),postprandial blood glucose(2 h PBG)and glycosylated hemoglobin(HbA1c)in the observation group were significantly lower than those in the control group(P<0.05);high density lipoprotein cholesterol(HDL-C)in the observation group was higher than that in the control group,while low density lipoprotein cholesterol(LDL-C),triglyceride(TG)and total serum cholesterol(TC)in the observation group were lower than those in the control group,with statistically significant difference(P<0.05);the left ventricular end-diastolic diameter(LVDd)in the observation group was lower than that in the control group,and the left ventricular short axis shortening rate(FS),ejection fraction(EF),and stroke output(SV)in the observation group were higher than those in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination of ertugliflozin and semaglutide in the treatment of type 2 diabetes patients with heart failure can significantly improve blood glucose and lipid indicators,improve cardiac function,and reduce body mass and blood pressure.
Type 2 diabetesHeart failureErtugliflozinSemaglutideBlood glucoseBlood lipidsCardiac function
万方数据
维普
